Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine

被引:6
|
作者
Erdogdu, Batuhan [1 ]
Cinar, Olgu Erkin [1 ]
Malkan, Umit Yavuz [1 ]
Aksu, Salih [1 ]
Demiroglu, Haluk [1 ]
Buyukasik, Yahya [1 ]
Goker, Hakan [1 ]
Sayinalp, Nilgun [1 ]
Haznedaroglu, Ibrahim Celalettin [1 ]
机构
[1] Hacettepe Univ, Fac Med, Dept Hematol, Ankara, Turkey
来源
关键词
D O I
10.4999/uhod.226097
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Our second case is a 49-year-old female patient, two days after receiving BNT162b2 mRNA COVID-19 vaccine, petechiae was started in arms and then in lower extremities. The complaints of weakness and fatigue continued to increase within days. The patient, who was admitted to the hospital ten days later with these complaints, was found to have bi-cytopenia. Bone marrow aspiration and biopsy reported that 20-30% stained with cd19 diffuse positive Terminal deoxynucleotidyl transferase (TdT) in blastic cells. HyperCVAD chemotherapy was started with the diagnosis of b-acute lymphoOur third case is a 57-year-old male patient, difficulty in swallowing, and oral ulceration after vaccination of BNT162b2 mRNA COVID-19 vac
引用
收藏
页码:65 / 67
页数:3
相关论文
共 50 条
  • [1] BNT162b2 COVID-19 vaccine
    不详
    AUSTRALIAN PRESCRIBER, 2021, 44 (02) : 57 - 58
  • [2] Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy
    Dagan, Noa
    Barda, Noam
    Biron-Shental, Tal
    Makov-Assif, Maya
    Key, Calanit
    Kohane, Isaac S.
    Hernan, Miguel A.
    Lipsitch, Marc
    Hernandez-Diaz, Sonia
    Reis, Ben Y.
    Balicer, Ran D.
    NATURE MEDICINE, 2021, 27 (10) : 1693 - +
  • [3] Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy
    Noa Dagan
    Noam Barda
    Tal Biron-Shental
    Maya Makov-Assif
    Calanit Key
    Isaac S. Kohane
    Miguel A. Hernán
    Marc Lipsitch
    Sonia Hernandez-Diaz
    Ben Y. Reis
    Ran D. Balicer
    Nature Medicine, 2021, 27 : 1693 - 1695
  • [4] BNT162b2 mRNA COVID-19 Vaccine: First Approval
    Lamb, Yvette N.
    DRUGS, 2021, 81 (04) : 495 - 501
  • [5] Cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine
    Lopez-Valle, Alba
    Falkenhain-Lopez, Daniel
    Arranz, Celia R.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2021, 60 (07) : 891 - 892
  • [6] Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
    Polack, Fernando P.
    Thomas, Stephen J.
    Kitchin, Nicholas
    Absalon, Judith
    Gurtman, Alejandra
    Lockhart, Stephen
    Perez, John L.
    Perez Marc, Gonzalo
    Moreira, Edson D.
    Zerbini, Cristiano
    Bailey, Ruth
    Swanson, Kena A.
    Roychoudhury, Satrajit
    Koury, Kenneth
    Li, Ping
    Kalina, Warren V.
    Cooper, David
    Frenck, Robert W., Jr.
    Hammitt, Laura L.
    Tureci, Ozlem
    Nell, Haylene
    Schaefer, Axel
    Unal, Serhat
    Tresnan, Dina B.
    Mather, Susan
    Dormitzer, Philip R.
    Sahin, Ugur
    Jansen, Kathrin U.
    Gruber, William C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (27): : 2603 - 2615
  • [7] Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
    Wang, Xiang
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16): : 1577 - 1578
  • [8] Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine
    Tumminia, Andrea
    Romano, Marcello
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (02): : 191 - 191
  • [9] BNT162b2 mRNA COVID-19 Vaccine: First Approval
    Yvette N. Lamb
    Drugs, 2021, 81 : 495 - 501
  • [10] Adverse events of a third dose of BNT162b2 mRNA COVID-19 vaccine among Korean healthcare workers
    Lee, Dong Yeop
    Kang, Dong Yoon
    Kim, Eunjung
    Lee, Se-joo
    Baek, Ji Hyeon
    Lee, Jin-Soo
    Park, Mi Youn
    Im, Jae Hyoung
    MEDICINE, 2023, 102 (11) : E33236